Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 117 full-time employees. The company went IPO on 2007-06-25. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
根據最新的財務報表(Form-10K),Allspring Income Opportunities Fund 的總資產為 $0,淨isProfitable}為 $0
NAGE 的關鍵財務比率是什麼?
Allspring Income Opportunities Fund 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Niagen Bioscience Inc 的收入按細分市場或地理位置如何劃分?
Allspring Income Opportunities Fund 最大收入來源為 Managed and Pub Partnership Sites,在最近的收益報告中收入為 871,900,000。就地區而言,United Kingdom 是 Allspring Income Opportunities Fund 的主要市場,收入為 897,900,000。
Niagen Bioscience Inc 是否盈利?
無,根據最新的財務報表,Allspring Income Opportunities Fund 的淨損失為 $0